BioSpace News Archive

Nalu Medical Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing.

Celularity Inc. announced expected net sales of its advance biomaterial products and biobanking businesses for the fourth quarter 2023 and the full year 2023 and expected total revenue for the fourth quarter 2023 and the full year 2023.

Omnia Medical announced that a trial date has been set for October 2024 in its ongoing lawsuit with PainTEQ.

The American Diabetes Association® welcomes the 2024 principal officers and board of directors.

First of its Kind Alliance Extends Mutual Service Offerings to Better Serve Clients

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024.

Cytokinetics, Incorporated announced that on December 29, 2023 it granted stock options to purchase an aggregate of 6,150 shares of common stock to three new employees, whose employment commenced in December 2023, as a material inducement to their employment.

Morphic Therapeutic (Nasdaq: MORF) today announced that Praveen Tipirneni, M.D., Chief Executive Officer of Morphic, has returned in full capacity from a previously announced temporary medical leave of absence and will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 3:45 PM PT/6:45 PM ET.

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd Annual J.P. Morgan Healthcare Conference.

Kyverna Therapeutics, Inc. (Kyverna) today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of multiple sclerosis (MS).